David Calhoun to Blood Pressure
This is a "connection" page, showing publications David Calhoun has written about Blood Pressure.
Connection Strength
17.689
-
Siddiqui M, Judd EK, Zhang B, Dudenbostel T, Carey RM, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. Hypertension. 2021 02; 77(2):435-444.
Score: 0.572
-
Kwon Y, Stafford PL, Lim DC, Park S, Kim SH, Berry RB, Calhoun DA. Blood pressure monitoring in sleep: time to wake up. Blood Press Monit. 2020 Apr; 25(2):61-68.
Score: 0.546
-
Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension. 2020 02; 75(2):510-515.
Score: 0.534
-
Flack JM, Calhoun D. The ACC/AHA and ESC/ESH Hypertension Guidelines: Contrasting Versions of Idiosyncratic Excellence. Am J Hypertens. 2019 07 17; 32(8):705-708.
Score: 0.520
-
Calhoun DA. The Year in Clinical Hypertension From Other Pages. Am J Hypertens. 2019 04 22; 32(5):441-444.
Score: 0.511
-
Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of Resistant and Refractory Hypertension. Circ Res. 2019 03 29; 124(7):1061-1070.
Score: 0.509
-
Calhoun DA, Schiffrin EL, Flack JM. Resistant Hypertension: An Update. Am J Hypertens. 2019 01 01; 32(1):1-3.
Score: 0.500
-
Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG, Oparil S, Calhoun DA. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018 08; 72(2):343-349.
Score: 0.481
-
Siddiqui M, Phillips RA, Bursztyn M, Sica D, Velasco A, Judd EK, Dudenbostel T, Lloyd SG, Oparil S, Calhoun DA. Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. Hypertension. 2018 07; 72(1):3-9.
Score: 0.478
-
Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. Am J Hypertens. 2017 May 01; 30(5):518-523.
Score: 0.446
-
Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017 01; 26(1):14-19.
Score: 0.436
-
Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017 02; 11(2):122-129.
Score: 0.435
-
Dudenbostel T, Calhoun DA. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. Am J Hypertens. 2017 Feb; 30(2):103-109.
Score: 0.426
-
Judd E, Calhoun DA. Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk. Hypertension. 2016 Feb; 67(2):275-7.
Score: 0.406
-
Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015 Mar; 22(2):116-22.
Score: 0.384
-
Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? Hypertension. 2014 Apr; 63(4):e84.
Score: 0.360
-
Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
Score: 0.359
-
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension. 2014 Mar; 63(3):e17-8.
Score: 0.358
-
Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014 Mar; 63(3):451-8.
Score: 0.352
-
Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
Score: 0.344
-
Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013; 64:233-47.
Score: 0.326
-
Pimenta E, Calhoun DA. Hypertensive crisis: forget the numbers. J Hypertens. 2012 May; 30(5):882-3.
Score: 0.315
-
Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, M?nard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 01; 124(18):1945-55.
Score: 0.303
-
Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.
Score: 0.297
-
Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2012 May; 26(5):281-7.
Score: 0.296
-
Ahmed MI, Calhoun DA. Resistant hypertension: bad and getting worse. Hypertension. 2011 Jun; 57(6):1045-6.
Score: 0.293
-
Acelajado MC, Pimenta E, Calhoun DA. Salt and aldosterone: a concert of bad effects. Hypertension. 2010 Nov; 56(5):804-5.
Score: 0.283
-
Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep; 54(3):475-81.
Score: 0.260
-
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007 Oct; 25(10):2131-7.
Score: 0.229
-
Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis. 2006 May-Jun; 48(6):387-96.
Score: 0.208
-
Nishizaka MK, Calhoun DA. Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. J Hypertens. 2006 Mar; 24(3):435-6.
Score: 0.206
-
Matanes F, Siddiqui M, Velasco A, Sharifov O, Kreps E, Dudenbostel T, Judd EK, Zhang B, Lloyd SG, Oparil S, Calhoun DA. Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension. J Clin Hypertens (Greenwich). 2023 05; 25(5):416-425.
Score: 0.168
-
Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, Feig DI, Redden DT, Muntner P, Foster PJ, Biggers-Clark SR, Mudano A, Sattui SE, Saddekni MB, Bridges SL, Saag KG. Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial. Arthritis Rheumatol. 2021 08; 73(8):1514-1522.
Score: 0.148
-
Thomas SJ, Siddiqui M, Judd E, Moore D, Harding SM, Oparil S, Calhoun D. Obstructive sleep apnea is more severe in men but not women with refractory hypertension compared with controlled resistant hypertension. J Hypertens. 2021 02 01; 39(2):286-291.
Score: 0.145
-
Langford AT, Akinyelure OP, Moore TL, Howard G, Min YI, Hillegass WB, Bress AP, Tajeu GS, Butler M, Jaeger BC, Yano Y, Shimbo D, Ogedegbe G, Calhoun D, Booth JN, Muntner P. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. Hypertension. 2020 11; 76(5):1600-1607.
Score: 0.141
-
Thomas SJ, Booth JN, Jaeger BC, Hubbard D, Sakhuja S, Abdalla M, Lloyd-Jones DM, Buysse DJ, Lewis CE, Shikany JM, Schwartz JE, Shimbo D, Calhoun D, Muntner P, Carnethon MR. Association of Sleep Characteristics With Nocturnal Hypertension and Nondipping Blood Pressure in the CARDIA Study. J Am Heart Assoc. 2020 04 07; 9(7):e015062.
Score: 0.136
-
Alper AB, Calhoun DA. Contemporary management of refractory hypertension. Curr Hypertens Rep. 1999 Oct; 1(5):402-7.
Score: 0.132
-
Calhoun DA, Zhu S. Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens. 1999 Apr; 17(4):507-12.
Score: 0.127
-
Johnson DA, Thomas SJ, Abdalla M, Guo N, Yano Y, Rueschman M, Tanner RM, Mittleman MA, Calhoun DA, Wilson JG, Muntner P, Redline S. Association Between Sleep Apnea and Blood Pressure Control Among Blacks. Circulation. 2019 03 05; 139(10):1275-1284.
Score: 0.127
-
Siddiqui M, Calhoun DA. Blood Pressure Measurement Challenges in Severely Obese Patients. Am J Hypertens. 2019 01 15; 32(2):139-140.
Score: 0.125
-
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 11; 72(5):e53-e90.
Score: 0.124
-
Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med. 2018 12; 131(12):1463-1472.e7.
Score: 0.122
-
Calhoun DA. Fluid retention, aldosterone excess, and treatment of resistant hypertension. Lancet Diabetes Endocrinol. 2018 06; 6(6):431-433.
Score: 0.119
-
Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Hypertens. 2018 01 12; 31(2):133-135.
Score: 0.117
-
Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope LM, Dudenbostel T, de la Sierra A. Prevalence and Clinical Characteristics of Refractory Hypertension. J Am Heart Assoc. 2017 Dec 07; 6(12).
Score: 0.116
-
Calhoun DA, Grassi G. True versus pseudoresistant hypertension. J Hypertens. 2017 12; 35(12):2367-2368.
Score: 0.116
-
Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
Score: 0.115
-
Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
Score: 0.111
-
Ghazi L, Dudenbostel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Oparil S, Calhoun DA, Rice M, Hage FG. Assessment of vascular function in low socioeconomic status preschool children: a pilot study. J Am Soc Hypertens. 2017 02; 11(2):101-109.
Score: 0.109
-
Dudenbostel T, Calhoun DA. Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. Am J Hypertens. 2017 01; 30(1):12-15.
Score: 0.108
-
Bhatt H, Ghazi L, Calhoun D, Oparil S. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out? Curr Cardiol Rep. 2016 10; 18(10):98.
Score: 0.107
-
Calhoun DA. Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. J Hypertens. 2016 09; 34(9):1701-3.
Score: 0.106
-
Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials. 2016 09; 50:238-44.
Score: 0.106
-
Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016 May; 34(5):1005-10.
Score: 0.104
-
Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016 06; 67(6):1085-92.
Score: 0.104
-
Zhu ST, Chen YF, Wyss JM, Nakao K, Imura H, Oparil S, Calhoun DA. Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. Hypertension. 1996 Feb; 27(2):297-302.
Score: 0.102
-
Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. Can J Cardiol. 2016 05; 32(5):603-6.
Score: 0.098
-
Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
Score: 0.097
-
Yano Y, Ning H, Muntner P, Reis JP, Calhoun DA, Viera AJ, Levine DA, Jacobs DR, Shimbo D, Liu K, Greenland P, Lloyd-Jones D. Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Hypertens. 2015 Oct; 28(10):1240-7.
Score: 0.096
-
Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, Yano Y, Viera AJ, Shimbo D. Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Hypertens. 2015 May; 28(5):640-8.
Score: 0.094
-
Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015 Apr; 29(4):241-6.
Score: 0.093
-
Calhoun DA, Zhu S, Wyss JM, Oparil S. Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats. Hypertension. 1994 Jul; 24(1):1-7.
Score: 0.092
-
Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 Oct; 64(4):731-7.
Score: 0.092
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
Score: 0.088
-
Calhoun DA, Lacourci?re Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013 Aug; 29(8):901-10.
Score: 0.085
-
Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013 Apr; 143(4):978-983.
Score: 0.084
-
Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):7-12.
Score: 0.076
-
Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011 Nov; 25(11):656-64.
Score: 0.074
-
Pimenta E, Calhoun DA. Treatment of resistant hypertension. J Hypertens. 2010 Nov; 28(11):2194-5.
Score: 0.071
-
Calhoun DA. Obstructive sleep apnea and hypertension. Curr Hypertens Rep. 2010 Jun; 12(3):189-95.
Score: 0.069
-
Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. Adv Ther. 2009 Nov; 26(11):1012-23.
Score: 0.067
-
Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug; 24(8):532-7.
Score: 0.067
-
Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009 Nov; 11(6):407-13.
Score: 0.066
-
Calhoun DA, Lacourci?re Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 Jul; 54(1):32-9.
Score: 0.064
-
White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008 Jun; 10(6):450-8.
Score: 0.060
-
Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006 Sep; 1(5):1039-45.
Score: 0.053
-
Nishizaka MK, Calhoun DA. Primary aldosteronism: diagnostic and therapeutic considerations. Curr Cardiol Rep. 2005 Nov; 7(6):412-7.
Score: 0.050
-
Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005 Jun; 18(6):805-12.
Score: 0.049
-
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec; 40(6):892-6.
Score: 0.041
-
White WB, Sica DA, Calhoun D, Mansoor GA, Anders RJ. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J. 2002 Oct; 144(4):657-65.
Score: 0.041
-
Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002 Aug; 1(8):621-36.
Score: 0.040
-
Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):221-8.
Score: 0.040
-
Matanes F, Khan MB, Siddiqui M, Dudenbostel T, Calhoun D, Oparil S. An Update on Refractory Hypertension. Curr Hypertens Rep. 2022 07; 24(7):225-234.
Score: 0.039
-
Kwon Y, Baruch M, Stafford PL, Bonner H, Cho Y, Mazimba S, Logan JG, Shimbo D, Park SH, Lin GM, Azarbarzin A, Calhoun DA, Berry R, Carey RM. Elucidation of obstructive sleep apnoea related blood pressure surge using a novel continuous beat-to-beat blood pressure monitoring system. J Hypertens. 2022 03 01; 40(3):520-527.
Score: 0.039
-
Calhoun DA, Wei CC, Zhu S, Bradley WE, Dell'Italia LJ. Enalaprilat blunts reflexive increases in cardiac interstitial norepinephrine in conscious rats. J Hypertens. 2001 Nov; 19(11):2025-9.
Score: 0.038
-
Aryal SR, Siddiqui M, Sharifov OF, Coffin MD, Zhang B, Gaddam KK, Gupta H, Denney TS, Dell'Italia LJ, Oparil S, Calhoun DA, Lloyd SG. Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. J Am Heart Assoc. 2021 09 07; 10(17):e019434.
Score: 0.038
-
Cai A, Liu L, Siddiqui M, Zhou D, Chen J, Calhoun DA, Tang S, Zhou Y, Feng Y. Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes. Am J Hypertens. 2021 02 18; 34(1):64-72.
Score: 0.036
-
Thomas SJ, Johnson DA, Guo N, Abdalla M, Booth JN, Spruill TM, Jackson CL, Yano Y, Sims M, Calhoun D, Muntner P, Redline S. Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens. 2020 10 21; 33(10):949-957.
Score: 0.035
-
Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019 09; 37(9):1797-1804.
Score: 0.033
-
Grassi G, Calhoun DA, Mancia G, Carey RM. Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines. Curr Hypertens Rep. 2019 07 18; 21(9):67.
Score: 0.032
-
Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Diaz Cambriles T, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Feced Olmos L, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019 06; 37(6):1269-1275.
Score: 0.032
-
Thomas SJ, Booth JN, Bromfield SG, Seals SR, Spruill TM, Ogedegbe G, Kidambi S, Shimbo D, Calhoun D, Muntner P. Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study. J Am Soc Hypertens. 2017 Apr; 11(4):204-212.e5.
Score: 0.027
-
Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017 Apr; 186:29-39.
Score: 0.027
-
Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. Am J Med. 2017 Apr; 130(4):439-448.e9.
Score: 0.027
-
Calhoun DA, Zhu ST, Chen YF, Oparil S. Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 1995 Aug; 26(2):285-9.
Score: 0.025
-
Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
Score: 0.023
-
Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H. Predictors of silent myocardial ischemia in resistant hypertensive patients. Am J Hypertens. 2015 Feb; 28(2):200-7.
Score: 0.023
-
Diaz KM, Booth JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014 Sep; 64(3):465-71.
Score: 0.023
-
Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.
Score: 0.022
-
Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension. 1993 Dec; 22(6):801-5.
Score: 0.022
-
Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014 Feb; 70(2):147-54.
Score: 0.022
-
Nakamura Y, Calhoun DA, Chen YF, Wyss JM, Oparil S. Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats. Hypertension. 1993 Sep; 22(3):285-91.
Score: 0.022
-
Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1583-90.
Score: 0.021
-
Eirin A, Zhu XY, Woollard JR, Herrmann SM, Gloviczki ML, Saad A, Juncos LA, Calhoun DA, Rule AD, Lerman A, Textor SC, Lerman LO. Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension. 2013 Sep; 62(3):585-91.
Score: 0.021
-
Calhoun DA. Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. Am J Med Sci. 1992 Nov; 304(5):306-11.
Score: 0.020
-
Gorelick PB, Nyenhuis D, Materson BJ, Calhoun DA, Elliott WJ, Phillips RA, Taler SJ, Townsend RR. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012 Sep-Oct; 6(5):309-15.
Score: 0.020
-
Alessi A, Brand?o AA, Coca A, Cordeiro AC, Cordeiro A, Nogueira AR, Di?genes de Magalh?es F, Feitosa A, Amodeo C, Saad Rodrigues CI, Rodrigues C, Calhoun DA, Calhoun D, Barbosa Coelho E, Barbosa E, Pimenta E, Muxfeldt E, Consolin-Colombo FM, Consolin-Colombo F, Salles G, Rosito G, Moreno H, Martin JF, Yugar JC, Aparecido Bortolotto L, Bortolotto L, Naz?rio Scala LC, Scala LC, Gon?alves de Sousa M, Souza Md, Gomes MA, Malachias MB, Gus M, Passarelli O, Jardim PC, Toscano PR, S?nchez RA, Sanchez R, Dischinger Miranda R, Miranda RD, P?voa R, Barroso WK. First Brazilian position on resistant hypertension. Arq Bras Cardiol. 2012 Jul; 99(1):576-85.
Score: 0.020
-
Grassi G, Seravalle G, Calhoun DA, Bolla GB, Zanchetti A, Mancia G. Alterations in sympathetic nerve traffic during cigarette-smoking in man: a preliminary report. J Hypertens Suppl. 1991 Dec; 9(6):S52-3.
Score: 0.019
-
Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012 Feb; 59(2):229-37.
Score: 0.019
-
Calhoun DA, Wyss JM, Oparil S. High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats. Hypertension. 1991 Mar; 17(3):363-8.
Score: 0.018
-
Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan; 25(1):217-26.
Score: 0.014
-
Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
Score: 0.012
-
Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67.
Score: 0.010
-
Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol. 2001 Nov; 281(5):C1413-21.
Score: 0.010
-
Sakawi Y, Tarpey M, Chen YF, Calhoun DA, Connor MG, Chestnut DH, Parks DA. Evaluation of low-dose endotoxin administration during pregnancy as a model of preeclampsia. Anesthesiology. 2000 Dec; 93(6):1446-55.
Score: 0.009
-
Fang Z, Sripairojthikoon W, Calhoun DA, Zhu S, Berecek KH, Wyss JM. Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens. 1999 Jul; 17(7):983-91.
Score: 0.008
-
Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del Bo A, Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994 Jul; 90(1):248-53.
Score: 0.006
-
Grassi G, Seravalle G, Calhoun DA, Mancia G. Physical training and baroreceptor control of sympathetic nerve activity in humans. Hypertension. 1994 Mar; 23(3):294-301.
Score: 0.006
-
Jin H, Yang RH, Calhoun DA, Wyss JM, Oparil S. Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat. Hypertension. 1992 Sep; 20(3):374-9.
Score: 0.005
-
Grassi G, Seravalle G, Calhoun D, Bolla GB, Mancia G. Physical exercise in essential hypertension. Chest. 1992 May; 101(5 Suppl):312S-314S.
Score: 0.005
-
Grassi G, Seravalle G, Calhoun DA, Bolla G, Mancia G. Cigarette smoking and the adrenergic nervous system. Clin Exp Hypertens A. 1992; 14(1-2):251-60.
Score: 0.005